Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that its Class 1 chemical drug HWH340 has received clinical approval from the National Medical Products Administration (NMPA). The drug is indicated for use in combination with abiraterone acetate for the treatment of advanced prostate cancer. This approval marks a significant step forward in the development of new therapeutic options for patients with this condition.
HWH340: Mechanism and Development
HWH340 is a PARP (poly(ADP-ribose) polymerase) inhibitor designed to target the repair mechanisms of cancer cells, thereby enhancing the efficacy of existing treatments. Currently, there are no PARP inhibitors approved for use in combination with abiraterone acetate for metastatic hormone-sensitive prostate cancer (mHSPC). This approval positions HWH340 as a potential first-in-class therapy in this indication.
Market Landscape
In October 2024, a combination therapy of niraparib (a PARP inhibitor) with abiraterone acetate and prednisone or prednisolone was approved for metastatic castration-resistant prostate cancer (mCRPC) patients with germline and/or somatic BRCA mutations. However, HWH340 represents a novel approach, targeting a different patient population with metastatic hormone-sensitive prostate cancer (mHSPC).-Fineline Info & Tech
Leave a Reply